Anne Louise Oaklander1,2, Francesca Gimigliano2,3. 1. Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. 2. Department of Pathology (Neuropathology), Massachusetts General Hospital, Boston, MA, USA. 3. Department of Mental and Physical Health, University of Campania "Luigi Vanvitelli", Naples, Italy.
Abstract
BACKGROUND: Chronic inflammatory demyelinating polyneuropathy (CIDP) is a potentially disabling health condition. OBJECTIVE: To assess the effects of different pharmacological interventions used in CIPD. METHODS: To summarize and to discuss the rehabilitation perspective on the published Cochrane Overview "Treatments for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): an overviewof systematic reviews" by Anne Louise Oaklander, et al., representing the Cochrane Neuromuscular Group. RESULTS: Five CSRs and 23 RCTs, reporting data on corticosteroids, plasma exchange and intravenous immunoglobulin, were considered in the overview. CONCLUSIONS: High quality trials investigating the combined effectiveness of drugs and exercise using ICF based outcomes should be encouraged.
BACKGROUND: Chronic inflammatory demyelinating polyneuropathy (CIDP) is a potentially disabling health condition. OBJECTIVE: To assess the effects of different pharmacological interventions used in CIPD. METHODS: To summarize and to discuss the rehabilitation perspective on the published Cochrane Overview "Treatments for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): an overviewof systematic reviews" by Anne Louise Oaklander, et al., representing the Cochrane Neuromuscular Group. RESULTS: Five CSRs and 23 RCTs, reporting data on corticosteroids, plasma exchange and intravenous immunoglobulin, were considered in the overview. CONCLUSIONS: High quality trials investigating the combined effectiveness of drugs and exercise using ICF based outcomes should be encouraged.
Authors: O Moranne; I M Ion; R Cezar; Z Messikh; C Prelipcean; S Chkair; E Thouvenot; Tu Anh Tran; P Corbeau; T Chevallier Journal: BMC Neurol Date: 2022-08-05 Impact factor: 2.903